�Results of a new analysis of the Treating to New Targets (TNT) study show that intensive low-density lipoprotein (LDL) cholesterol-lowering in patients with stable coronary heart disease (CHD) whose systolic blood pressure level was less than one hundred forty mmHg rock-bottom the risk of major cardiovascular events, including eye attack, stroke and resuscitated cardiac halt, by 42 percent compared with less intensive LDL lowering and uncontrolled blood pressure of 140 mmHg or higher.
Led by John B. Kostis, MD, the John G. Detwiler prof of cardiology, professor of medicine and chair, department of practice of medicine, UMDNJ-Robert Wood Johnson Medical School, UMDNJ-Robert Wood Johnson Medical School, and chief of medical service at Robert Wood Johnson University Hospital, this post-hoc analytic thinking of the five-year 10,001 affected role TNT sketch that was funded by Pfizer, Inc., was published in the May 2008 issue of the Journal of Clinical Hypertension.
"People world Health Organization have both high cholesterol and high blood press are at greater danger for cardiovascular disease than those with either condition alone.Yet, a minority of patients with both conditions is treated to currently recommended targets. In one study less than a third of such patients were treated and only one in ten were treated to target," aforementioned Dr. Kostis. "The analysis reported today reminds us that intensive management of both cholesterin and
